Evomela® (melphalan) – Indication withdrawal
August 9, 2021 - The FDA approved the voluntary removal of Acrotech Biopharma’s Evomela (melphalan) indication for palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
Download PDF
